Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The trial is a multicentre, prospective, open-label, blinded endpoint (PROBE), phase 3,
randomized controlled design. Patients with acute ischemic stroke due to basilar artery
occlusion presenting within 24 hours will be randomized 1:1 to intravenous tenecteplase
(0.25mg/kg, maximum 25mg) ± thrombectomy or 'best practice'which may be alteplase (0.9mg/kg)
within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating
clinician's discretion.